AA Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206).

Trial Profile

AA Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206).

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs AFM 13 (Primary) ; Pembrolizumab
  • Indications Hodgkin's disease
  • Focus Adverse reactions
  • Acronyms KEYNOTE- 206
  • Sponsors Affimed Therapeutics
  • Most Recent Events

    • 01 Aug 2017 According to an Affimed media release, the company has completed the escalation phase and initiated the dose expansion cohort.
    • 30 Mar 2017 According to an Affimed Therapeutics media release, company has completed recruitment into the third dose cohort. Further update on the study is expected in the second half of 2017.
    • 11 Jan 2017 According to an Affimed Therapeutics media release, company completed recruitment in the second dose cohort. Further updates on the study are expected in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top